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Background: Praziquantel (PZQ) is an antihelminthic drug whose P-glycoprotein (P-gp) substrate specificity has not
been conclusively characterized. We investigated its specificity by comparing its in vitro intracellular accumulation
in CEM (parental), and CEMVBL cells which over express P-gp, a drug efflux transporter. Saquinavir (SQV), a known
substrate of efflux transporters was used as control.
Methods: A reversed phase liquid chromatography method was developed to simultaneously quantify PZQ and
SQV in cell culture media involving involved a liquid - liquid extraction followed by ultra-high performance
liquid chromatography using a Hypurity C18 column and ultraviolet detection set at a wavelength of 215 nm.
The mobile phase consisted of ammonium formate, acetonitrile and methanol (57:38:5 v/v). Separation was
facilitated via isocratic elution at a flow rate of 1.5 ml/min, with clozapine (CLZ) as internal standard. This
was validated over the concentration range of 1.6 to 25.6 μM for all analytes. Intracellular accumulation of
SQV in CEMVBL was significantly lower compared to that in CEM cells (0.1 ± 0.031 versus 0.52 ± 0.046, p = 0.03
[p <0.05]).
Results: Accumulation of PZQ in both cell lines cells were similar (0.05 ± 0.005 versus 0.04 ± 0.009, p = 0.4)
suggesting that it is not a substrate of P-gp in CEM cells. In presence tariquidar, a known inhibitor of P-gp,
the intracellular accumulation of SQV in CEMVBL cells increased (0.52 ± 0.068 versus 0.61 ± 0.102, p = 0.34 in
CEM cells and 0.09 ± 0.015 versus 0.56 ± 0.089, p = 0.029 [p < 0.05] in CEMVBL cells). PZQ did not significantly
affect the accumulation of SQV in either CEM (0.52 ± 0.068 versus 0.54 ± 0.061, p = 0.77), or in CEMVBL cells
(0.09 ± 0.015 versus 0.1 ± 0.031, p = 0.89) cells compared to tariquidar, implying that PZQ is not an inhibitor of
P-gp in CEMVBL cells.
Conclusions: PZQ is neither a substrate nor an inhibitor of the efflux drug transporter P-gp in T-lymphoblastoid cells,
CEM and CEMVBL. We also report a simple, accurate and precise method for simultaneous quantification of
PZQ and SQV.
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Praziquantel (PZQ) is a broad spectrum antihelminthic
drug used in the mass treatment of lymphatic filariasis
and schistosomiasis which afflicts over 243 million
people [1, 2]. It is widely used because of its low cost
and efficacy. It is also used in combination with albenda-
zole for the treatment of neurocystercosis [3]. The three
conditions constitute serious public health problems
in the developing countries of Africa, Asia and Latin
America [4, 5]. The same regions bear the burden of
HIV/AIDS, especially sub-Saharan Africa. Praziquantel
is therefore quite often co-administered with several other
drugs including antiretroviral drugs [ARVs] [6–9]. The co-
administration may give rise to drug-drug interactions
that could influence the treatment outcomes, which in
some instances may require dosage adjustments in order
to prevent toxicity or resistance [10–12]. Despite its wide-
spread use, there is currently limited information regard-
ing PZQ’s mechanisms of action at molecular level, and a
lot more research is required in its pharmacokinetics in
order to prevent resistance [13].
A possible mechanism for interactions between drugs
results from the modulation of the efflux drug trans-
porter, P-gp. P-gp functions to transport drugs from the
intracellular to the extracellular domain, often against
concentration gradients. The inhibition or potentiation
of the transporter function will therefore have an im-
pact on the cellular accumulations of the drug’s effi-
cacy [14, 15]. Several drugs are substrates and/or
inhibitors of efflux drug transporters and metabolic en-
zymes (especially CYP 3A4). Among the ARVs, protease
inhibitors (PIs) including SQV are known to be substrates
of P-gp, ABCC 1 and ABCC 2 [14, 16, 17]. With regards
to drug transporter specificity, PZQ has not been conclu-
sively characterized to date. In one study, the authors
concluded that PZQ is an inhibitor of P-gp without being
a substrate [18], whereas those in a related study indicated
that PZQ did not show potential for interacting with
cellular efflux pumps despite being a highly permeable
substance [19, 20]. PZQ has also been reported to inhibit
the transport by SMDR2, a P-gp orthologue from S.
mansoni [21], and P-gp has also been postulated to play a
role in the resistance of PZQ [22–24].
The intracellular accumulation of drugs is con-
trolled by several factors including ion trapping, lipo-
philicity and plasma protein binding, as well as influx
and efflux transporters. With regards to PIs, drug
transporters P-gp, ABCC1, ABCC2 and BCRP play an
important role in their accumulation [25, 26]. Being
an efflux transporter, P-gp transports PIs from the
intracellular to extracellular compartments, and the
differences in their accumulation may be used to
study their pharmacokinetics [15]. CEM cells treated
with vinblastine (CEMVBL) overexpress P-gp [27], andthe comparison of the in vitro accumulation of PIs in
CEM parental and CEMVBL cells has been used to investi-
gate the effects of active transport [15, 28]. Previous stud-
ies in our laboratory have investigated the intracellular
accumulation of SQV in T-lymphoblastoid cells, CEM
parental and CEMVBL cells [25].
Our study had a double objective; to develop a suitable
assay method for simultaneous quantification of both
PZQ and SQV and to characterize PZQ with regards to
substrate specificity of the transporter P-gp. In order to
ascertain whether PZQ is a substrate of P-gp, its intra-
cellular accumulation in CEM parental and CEMVBL
cells which overexpress P-gp were compared to that of
SQV, a known substrate of P-gp [15, 25, 28]. To deter-
mine whether it is an inhibitor, the accumulation of
SQV in CEMVBL cells was compared to its accumulation
in presence of PZQ, and in presence of a known inhibi-
tor, tariquidar (XR). A reversed phase liquid chromatog-
raphy method was validated for simultaneous
quantification of both PZQ and SQV in cell culture
media and cell pellets.
Methods
Chemicals and reagents
SQV (Formula weight, 670.86) was donated by Roche
Pharmaceuticals (Welwyn Garden City, UK). PZQ (cat.
no. P4668, formula weight, 312.41); Clozapine [CLZ]
(cat. no. C6305, Formula Weight, 326.82); Dulbecco’s
Modified Eagle’s Medium, [DMEM] (cat. no. D6249,
containing 4500 mg/L glucose, 4 mM L-glutamine and
110 mg/L sodium pyruvate); Hanks Balanced Salt Solu-
tion [HBSS] (cat. no. H8264, modified with sodium
bicarbonate, without phenol red, liquid, sterile-filtered,
cell culture tested); Roswell Park Memorial Institute
medium [RPMI] (cat. no. R8758)]; Foetal Bovine
Medium, FBS (cat. F7524) and Trypsin-EDTA solution
were purchased from Sigma Chemical Co. (Poole, UK).
Acetonitrile (ACN) and methanol (MeOH) were pur-
chased from VWR international (Leicestershire, UK);
whereas diethyl ether was purchased from Fisher Scien-
tific, (Leicestershire, UK). Tariquidar was kindly donated
by Xenova Group plc (Berkshire, UK). All the other che-
micals used were of analytical or HPLC grade. Deionised
water used to prepare the solutions or mobile phase was
purified in an Elga DV 25 pure lab option system (Elga,
High Wycombe, Bucks, and UK). T-lymphoblastoid cell
lines, CEM and CEMVBL cells were gifts from Dr. R.
Davey (University of Queensland, Australia), and the
cells were counted using a Nucleo Counter (ChemoMe-
tec, Denmark) cell counter.
Equipment and chromatographic conditions
The high performance liquid chromatography (HPLC)
consisted of a Dionex (Dionex Softron GmbH, Germany)
Table 1 Concentrations of the standards and QCs
Tube No. Levels SQV/PZQ Conc.(μM) Stock(μl) DMEM(μl)
1,2 1 0 0 100
3,4 2 1.6 6.25 93.75
5,6 3 3.2 12.5 87.5
7,8 4 6.4 25 75
9,10 5 12.8 50 50
11,12 6 19.2 75 25
13,14 7 25.6 100 0
Total 268.75(μl) 431.25(μl)
QCs
15,16 LQC 6.4 100 0
17,18 MQC 12.8 100 0
19,20 HQC 19.2 100 0
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mated sample injector and a UVD 1704 detector. A
250 μl injector with a 20 μl loop was used. Reversed-
phase-liquid chromatography was carried out using a
Hypurity™ C18 analytical column, 5 μm× 4.6 mm
(Thermo Electron Corporation, Runcorn, UK 22105-
154630). A column guard (Thermo electron 60140-412)
was used to protect the analytical column. The ultravio-
let detector was set to monitor at 215 nm wavelength.
The mobile phase for the analysis was composed of
ammonium formate 20 mM (pH = 4.2), ACN and MeOH
(57:38:5 v/v), and was prepared fresh for each assay.
The separation was facilitated via isocratic elution at
1.5 ml/min flow rate and the run time was eight mi-
nutes for each separation. 20 μl of the samples was
injected for each run by means of an automated in-
jector. The peak area ratios for the calibration curves
and quantification were obtained and analyzed using
Chromelon software (version 6.5).
Preparation of stock solutions, calibrators, quality
controls and internal standard
Stock solutions
Stock ammonium formate buffer was prepared by dis-
solving ammonium formate in deionised water to obtain
a final concentration of 1 M (63.06 mg/ml). The pH was
then adjusted by the addition of formic acid to 4.2 M,
and stored at room temperature. This was stable for use
for up to 6 months. Stock standard solutions of SQV,
PZQ and the internal standard (IS), clozapine were
prepared by dissolving the various solutions of the
analyte in MeOH to obtain a final concentration of
1 mg/ml. They were then capped, labeled and stored
at 4 °C until use.
Working solutions
Working ammonium formate buffer (20 mM [1.26 mg/ml])
was prepared by diluting the stock buffer with deionised
water, 1:50 (v/v). Working stock standard solutions (100 μl
each) of PZQ and SQV were prepared by appropriate
dilution in DMEM media over a concentration range of 1.6
to 25.6 μM in duplicate (six concentration levels). Quality
control (QC) samples (100 μl) were prepared by diluting
the stock solutions of the analytes to give QC concentra-
tions of 6.4 (LQC), 12.8 (MQC) and 19.2 μM (HQC). Suffi-
cient volume of the working internal standard (5 μg/ml)
was prepared fresh for each assay in a serial dilution
of the stock CLZ solution in MeOH, first as 1 in 10
to give 10 μg/ml followed by 1 in 2.
Calibration curves
Working stock standard solutions of PZQ and SQV were
prepared by appropriate dilution in DMEM media. For
the construction of the calibration curve, 100 μl of thecalibration standards were prepared by serial dilution of
the stock SQV/PZQ solutions in DMEM (in duplicate),
after thawing the samples resulting in seven concentra-
tion levels of 0, 1.6, 3.2, 6.4, 12.8, 19.2 and 25.6 μM in
10 ml labelled glass tubes (Table 1). Quality control sam-
ples (100 μl) were prepared by thawing the stock QC
samples and pipetting into separate 10 ml labelled glass
tubes (in duplicate) to give concentrations of 6.4 (LQC),
12.8 (MQC) and 19.2 μM (HQC).Extraction procedure
Before the analysis, 100 μl of the calibration standards
and QCs were pipetted in duplicate into 10 ml labeled
glass tubes. 20 μl of 5 μg/ml of internal standard CLZ
and 2mls of the extraction solvent diethyl ether were
then added to each individual sample using a Finn re-
peater pipette. The tubes were then capped and tumbled
for 30 min using a rotary mixer and then centrifuged for
5 min at 4000 × g. The aqueous phase was then frozen in
a cryogenic bath and the solvent phases transferred to
correspondently labelled 5 ml clean tubes. This was
followed by evaporation of the solvent to dryness using a
centrifugal rotary evaporator (Jouan RC.10.10). The resi-
dues were reconstituted by the addition of 100 μl mobile
phase and all the tubes vortexed. 100 μl of the samples
were then aliquoted into autosampler vials, placed in
corresponding numbered wells of the autosampler
tray and securely capped. They were then centrifuged
for 4 min at 4000 × g, and injected into the HPLC
column (20 μl).Method validation
The validation of the method was carried out as per the
FDA guidelines.
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In order to evaluate the linearity of the assay, ten six-
point (1.6, 3.2, 6.4, 12.8, 19.2 and 25.6 μM) calibration
curves were analyzed on separate days to determine the
concentrations for each sample. The samples were
extracted as described on section “Extraction procedure”
and the standard curves were plotted as the peak area
ratio (PAR) of the respective compound to the internal
standard versus the concentration. The curves were
obtained by the use of DMEM spiked with each of the
six concentrations of both SQV and PZQ on the same
run, and each point in the calibration curve run in dupli-
cate. To assess linearity, the line of best fit was then
determined by least squares regression.
Limit of quantification
The lowest limit of quantification (LLQ) for each
drug was the minimal concentration that was within
the range of the nominal concentration, with the ac-
ceptance criteria for each calculated standard concen-
tration limited to not more than 20 % deviation from
the nominal value. Calibration curves were established
with standard solutions for the concentration points
of 1.6, 3.2, 6.4, 12.8, 19.2 and 25.6 μM, all analyzed
in quadruplicate.
Limit of detection
To determine the limit of detection (LLD), quadruplicate
standard solutions for the concentration points of 1.6,
0.8, 0.4, 0.2, 0.1 and 0.05 μM in were analyzed, and the
peak areas of the respective drug concentration com-
pared to that in DMEM (blank). The lowest concentra-
tion that produced a signal three or more times above
the noise level of a blank preparation was designated as
the limit of detection (LOD).
Accuracy and precision
Inter-day accuracy and precision ware evaluated by com-
paring ten replicate low, medium and high QC levels
that were analyzed on different days. The intra-day ac-
curacy and precision was determined by the analysis of
the three concentrations of the QC samples in six repli-
cates within the same day, evaluated in duplicate. The
obtained results were expressed as relative standard de-
viations to the mean and the Coefficient of variation
(CV) expressed as a percentage; that is CV = (SD/
Mean) × 100. The accuracy and precision of the analyt-
ical method was based on the fact that the relative
standard deviation of each concentration should be
within ± 20 % of the nominal concentration.
Recovery
The recovery or extraction efficiency of the analyte
after the liquid-liquid extraction was determined bycomparing the peak areas of six replicate samples of
the QCs of each compound in extracted DMEM to
those of non-processed standard solutions (standard
solutions spiked in mobile phase). It was expressed as
a percentage of the peak area of the extracted drug
to that injected in MP.
Specificity, selectivity and stability
The separation from endogenous compounds was inves-
tigated by analyzing six different samples of DMEM.
Short and long term stability was investigated by com-
paring the peak areas of six freshly prepared QC assay
samples to those of the freeze-thawed samples, and it
was expressed as a percentage.
Drug accumulation experiments
Cell culture
The parental cell line was CEM (T-lymphoblastoid cell
line) was used as the parental cell line. CEMVBL cells
that have increased expression of P-gp were selected
under vinblastine [25]. The selection of drug resistant
cells was carried out by using increasing concentrations
of vinblastine up to 100 ng/mL. CEM and CEMVBL Cells
were cultured in 175 cm2 flasks containing DMEM sup-
plemented with 15 % FBS at 37 °C in a humidified 5 %
CO2 gassed incubator, conditions which led to doubling
after approximately every 24 h. Aliquots (100 μl) of
CEM and CEMVBL Cells were then counted using
Nucleo Counter (Chemometec, Denmark) and the ap-
propriate volume containing 10 million cells was trans-
ferred into eight 20 ml sterilin tubes, appropriately
labelled for the following samples: CEM PZQ, VBL PZQ,
CEM SQV and VBL SQV [n = 2].Intracellular accumulation of PZQ and SQV in CEM and
CEMVBL cells
The cell samples were centrifuged (2000 × g for 5 min at
4 °C) and the supernatant fraction discarded. A total of
10 ml of fresh DMEM media was added to the resulting
pellets to give a concentration of 1 million cells/ml, and
100 μl of 1 mg/ml of both PZQ and SQV to each re-
spective tube resulting in a concentration of 10 μg/ml.
The cells were then incubated at 37 °C for 30 min in a
shaking water bath. The resulting cell suspensions were
then centrifuged (2000 × g for 5 min at 4 °C). 100 μl
samples of the supernatant fraction were then removed,
and the aliquots used to determine the extracellular
(EXT) concentration. The excess supernatant fraction
was then discarded and the resulting cell pellet washed
three times in 10 ml HBSS and centrifuged (2000 × g
for 5 min). The resulting pellets were solubilized by
reconstituting in 100 μl of distilled water and used to
determine intracellular (INT) concentrations as described
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The experiment was carried out in quadruplicate. The
samples were then assayed by HPLC, and the data
expressed as cellular accumulation ratio (CAR), the ratio
of the intracellular to the extracellular accumulation cal-
culated by the formula, CAR = (INT/EXT) × 10 [intracel-
lular concentrations were calculated using the volume of a
single CEM and CEMVBL cell to be 1 picolitre (pl)] [15,
30].
Effect of PZQ and tariquidar on the intracellular
accumulation of SQV in CEM and CEMVBL cells
In the inhibition study, the cells (CEM and CEMVBL)
spiked with a concentration of 10 μg/ml of SQV were
incubated alone, and in the presence of 10 μg/ml PZQ;
and 1 μM tariquidar (XR) respectively.
Data analysis
Statistical analysis was determined by Mann-Whitney
U test. All results were presented as mean ± S.D.
with 95 % confidence intervals for the difference be-
tween the means, where appropriate. Statistical ana-
lysis was performed by using the unpaired t-test and




The analysis of SQV and PZQ on the same mobile phase
was highly dependent on the pH value of the mobile
phase. Thus, the reverse-phase analysis was initially per-











Fig. 1 Chromatogram depicting the retention times of CLZ (internal standaACN and MeOH. The composition of the final mobile
phase was 57 % ammonium formate, 38 % ACN and 5 %
MeOH. These conditions yielded satisfactory and repro-
ducible retention times of both PZQ and SQV. CLZ was
found to be the most suitable internal standard. A sam-
ple chromatogram of SQV, PZQ and CLZ is represented
in Fig. 1. The retention time for SQV was 5.1 min,
whereas PZQ had 6.2 min and CLZ 2.2 min, with the
total run time being 8 min. Detection at 215 nm pro-
vided adequate sensitivity.Linearity, limit of quantification and limit of detection
The lower limit of quantification for both SQV and PZQ
on the same run was 1.6 μM whereas the upper limit of
quantification was 25.6 μM. The concentration-response
relationship for both SQV and PZQ standards was found
to be linear in the concentration range of 1.6–25.6 μM
(r = 0.99773 for PZQ and r = 0.9962 for SQV) (Fig. 2).
This linear relationship was demonstrated by a coeffi-
cient of variation obtained from the daily standard
curves used for the analysis of unknown samples. The
lowest limit of quantification (LLQ) was 1.6 μM, while
the LLD was 0.1 μM for both drugs.Accuracy and precision
The mean inter-day precision was within the range for
both drugs with average CVs of between 3.28 and 5.89 %
for PZQ, and 3.67 and 9.32 for SQV (Table 2). Similarly,
the intra-day assay values were between 0.97 to 2.13 for
PZQ and 0.86 to 2.15 for SQV (Table 2).(min)
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Fig. 2 Plots of the calibration curves showing the concentration response relationships of a (PZQ) and b (SQV) on the same run
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Table 2 Inter-day/intra-day precision, percentage recovery and stability
Drug Inter-day precision Intra-day precision Percentage recovery (%) Stability
Mean CV (%) Mean CV (%) Mean CV (%) Mean CV (%)
PZQ
LQC 6.29 (±0.37) 5.89 6.71 (±0.03) 3.89 106 (±14) 13.83 105 (±4) 3
MQC 12.78 (±0.58) 4.06 11.67 (±0.14) 4.06 115 (±6) 5.59 113 (±6) 5
HQC 19.38 (±0.64) 3.03 18.92 (±0.84) 4.54 115 (±3) 3.03 109 (±3) 3
SQV
LQC 6.23 (±0.58) 9.32 6.68 (±0.58) 4.32 95 (±6) 7.28 91 (±5) 6
MQC 12.8 (±0.93) 7.24 12.61 (±0.18) 7.24 110 (±10) 9.58 100 (±5) 5
HQC 18.94 (±0.69) 3.67 19.63 (±0.91) 3.69 101 (±4) 4.46 87 (±2) 2
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The mean recovery for both drugs in DMEM was always
greater than 92 % for both drugs within the analyzed
concentration range of 6.4 μM (MQC) to 19.2 μM
(HQC) (Table 2).Specificity and selectivity
The selectivity of the chromatographic separation was
demonstrated by the absence of interfering endogenous
peaks in DMEM (Fig. 3).Stability
Freeze thawing DMEM samples containing SQV and
PZQ did not appear to significantly affect the concentra-











Fig. 3 Chromatogram of the blank extract (DMEM), showing the injectionAccumulation experiments
The chromatograms illustrating the extracellular
and intracellular accumulation of both SQV and
PZQ in CEM and CEMVBL cells are depicted in
Fig. 4. The accumulation of SQV was significantly
lower in CEMVBL than CEM cells (0.1 ± 0.031 ver-
sus 0.52 ± 0.046, p = 0.03 [p <0.05]), whereas similar
accumulation of PZQ occurred in both cell lines
(0.05 ± 0.005 versus 0.04 ± 0.009, p = 0.4) [Table 3;
Fig. 5].
PZQ did not significantly affect the accumulation of
SQV in either CEM (0.52 ± 0.068 versus 0.54 ± 0.061,
p = 0.77), or in CEMVBL cells (0.09 ± 0.015 versus 0.1
± 0.031, p = 0.89) cells as compared to tariquidar;
0.52 ± 0.068 versus 0.61 ± 0.102, p = 0.34 in CEM cells
and 0.09 ± 0.015 versus 0.56 ± 0.089, p = 0.029 [p <
0.05] in CEMVBL cells (Table 4; Fig. 6).ime (min)
peak and absence of any other interfering peaks
a. CEMSQV/PZQ extracellular
b.  VBLSQV/PZQ extracellular
c. VBL SQV/PZQ intracellular
Fig. 4 Chromatograms showing the extracellular accumulation of SQV/PZQ in CEM parental (a), and CEMVBL cells (b); and intracellular accumulation in
CEMVBL cells (c)
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The purpose of this research was to characterize the P-gp
substrate specificity of PZQ, a widely used drug as an at-
tempt to understand its pharmacokinetics. This was done
by investigating its intracellular accumulation in T-
lymphoblastoid cells, CEM parental and CEMVBL cells
which overexpress P-gp. A reversed phase HPLC method
was developed for quantification.
P-gp plays an important role in the movement of
many drugs across biological membranes, especiallythose administered through the oral route. It functions
as a transmembrane efflux pump; pumping its substrates
outside the cells, hence affecting its tissue concentra-
tions and resultant pharmacological effects, including
drugs interactions and resistance [31–34]. The inhibition
or potentiation of the transporter function will therefore
have an impact on the cellular accumulations of the drugs
and efficacy, an example being the reported reduction in
plasma concentrations of PIs [35–38]. In addition, the
efflux protein is present in several important body
Table 4 Cellular accumulation ratio values for inhibition studies








1 0.57 0.45 0.55 0.07 0.08 0.53
2 0.50 0.57 0.51 0.10 0.07 0.50
3 0.59 0.59 0.73 0.10 0.13 0.69
4 0.44 0.53 0.66 0.11 0.13 0.52
Mean 0.52 0.54 0.61 0.09 0.10 0.56
STDEV 0.068 0.061 0.102 0.015 0.031 0.089
p value p = 0.77 p = 0.34 p = 0.89 p = 0.03
Table 3 Cellular accumulation ratio (CAR) values for the
substrate studies
Sample CEM SQV VBL SQV CEM PZQ VBL PZQ
1 0.54 0.12 0.03 0.06
2 0.52 0.14 0.05 0.05
3 0.45 0.07 0.05 0.05
4 0.55 0.08 0.04 0.05
Mean 0.52 0.10 0.04 0.05
STDEV 0.046 0.031 0.009 0.005
p value p = 0.03 p = 0.4
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and placenta where it has role in modulating its sub-
strate drugs [39, 40]. P-gp along with CYP 450 group of en-
zymes are therefore important determinants of the
pharmacokinetics of several drugs, since many are its sub-
strates. The determination of the substrate specificity of a drug
to either efflux proteins and/or metabolizing enzymes is there-
fore important in the understanding of its pharmacokinetics
[41–44]. Indeed, the substrate specificity of several drugs to P-
gp has now been characterized [32, 45].
Despite its widespread use, PZQ’s substrate specificity
to P-gp has not been conclusively characterized, since
authors from previous studies arrived at conflicting con-
clusions. Researchers from two groups concluded that it
was not a substrate [19, 20], whereas another team con-
cluded that it was an inhibitor without being a substrate
[18]. However, it is noteworthy that Caco-2 cell lines used
by the second group express several drug transporters (in-
flux as well as efflux) including metabolic enzymes. An
interplay of several factors is therefore possible, and care-
ful interpretation of the results may be necessary [46–49].
In order to determine the P-gp substrate specificity
of PZQ, we developed an analytical method that com-
pared intracellular accumulations of the drug in T-
lymphoblastoid cells, CEM (control) and CEMVBL which
overexpress P-gp, alone and in presence of SQV, a known















Fig. 5 Intracellular accumulation of SQV and PZQ in CEM and
CEMVBL cells, Mean ± SD (n = 4)to quantify PZQ levels, alone [50, 51] or in combination
with other drugs [52–54]; but none so far for simultan-
eous determination of the drug and ARVs. We chose to
use SQV, a PI as PZQ may be co-administered with PIs,
since there is geographic overlap between the regions
afflicted by both Schistosomiasis and HIV/AIDS [55]. The
method was validated over a concentration range of 1.6 to
19.2 μM for both drugs (50 to 600 ng/ml for PZQ and 107
to 1288 ng/ml for SQV); which is within the detectable
range for both drugs in human plasma [56, 57].
Conclusion
The results from our accumulation results indicate that
PZQ is neither a substrate nor an inhibitor of P-gp in T
lymphoblastoid cells, CEM and CEMVBL. We also report
a simple, accurate and precise method for simultaneous
quantification of PZQ and SQV. Several HPLC methods
have been developed for the determination of PZQ alone
[50, 51], or simultaneously with other antihelminthics
[58, 59]. However, to date there is none reported in the lit-
erature that has been developed for concurrent analysis of
antiretroviral and antihelminthic drugs. We for the first
time report a simple and accurate HPLC method for the
simultaneous quantification of PZQ and SQV. This
method may be used to investigate the pharmacokinetics
of PZQ, including the potential drug interactions be-























Fig. 6 Effect of PZQ and tariquidar on the intracellular accumulation
of SQV in CEM and CEMVBL cells, Mean ± SD (n = 4)
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